## **HEALTHY U** MEDICAID

## PRIOR AUTHORIZATION REQUEST FORM

## **ACUTE MIGRAINE**

D.H.E 45®, Migranal®, Nurtec™, Reyvow™, Treximet®, Ubrelvy®, Zavzpret™

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.									
If	If you have prior authorization questions, please call for assistance: 385-425-5094								
Di	Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.								
Da	ate:	Member Name:		ID#:					
DC	B: Gender:		Physician:						
Of	ffice Phone: Office Fax:		Office Contact:						
Нє	Height/Weight:								
preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.  Product being requested:  Preferred: □ generic triptan medications (e.g., almotriptan, sumatriptan, rizatriptan), □ Ubrelvy® (ubrogepant)  Non-Preferred: □ Nurtec™ (rimegepant)  Non-Formulary: □ dihydroergotamine mesylate injection, □ dihydroergotamine mesylate nasal spray, ODT, □ Reyvow™ (lasmmiditan), □ Treximet® (sumatriptan and naproxen sodium), , □ Zavzpret™ (zavegepant) nasal spray  Dosing/Frequency: □ Dosing/Frequ									
Do	osing/Frequency:								
Do		s for reauthorization, proceed	to reau	ıthorizat	ion section.				
Do			to reau	ıthorizat No	ion section.  Comments/Notes				
	If the request is	S							
1.	If the request is  Question Is the request made by, or in consu	s Iltation with, a neurologist or	Yes	No					
1. 2. 3.	If the request is  Question  Is the request made by, or in consumer of the request made by, or in consumer of the request made by, or in consumer of the request made	either: Inche days per month? Its per month AND taking a depressant, anticonvulsant, in channel blocker)?	Yes	No	Please provide documentation  Please provide documentation				
1. 2. 3.	If the request is  Question  Is the request made by, or in consumer to the specialist?  Does the member have a documer with or without aura?  Does clinical documentation show  • Member has less than 15 heada  • Member has ≥ 15 headache day prophylactic agent (e.g. an anticomposition)	either: Inche days per month? Is per month AND taking a depressant, anticonvulsant, in channel blocker)? Iure or least two preferred generic aximum FDA-approved AND either a nasal spray or atriptan, rizatriptan,	Yes	No	Comments/Notes  Please provide documentation				

6. Is the member taking a Calcitonin Gene-Related Peptide (CGRP) medication to prevent migraine headaches?			Please provide documentation				
DIHYDROERGOTAMINE MESYLATE NASAL SPRAY							
<ol> <li>Has the member had a trial and failure, or intolerance, to dihydroergotamine injection?</li> </ol>			Please provide documentation				
TREXIMET							
1. Has the member tried and found to be intolerant to the			Please provide documentation				
inactive ingredients in both naproxen sodium and sumatriptan?							
REAUTHORIZATION							
1. Is the request for reauthorization of therapy?							
2. Does documentation show the member has a positive clinical response to therapy?			Please provide documentation				
3. Is the member taking a Calcitonin Gene-Related Peptide (CGRP) medication to prevent migraine headaches?			Please provide documentation				
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.							
Additional information:  Physician Signature:							

\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\*

Policy PHARM-HU-088
Origination Date: 01/01/2022
Reviewed/Revised Date: 03/27/2024
Next Review Date: 03/27/2025
Current Effective Date: 04/01/2024

## **Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.